Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0076 • ACR Convergence 2023
Characterizing GMCSF Producing T-cells in Rheumatoid Arthritis and Effect of Methotrexate on Them
AASTHA KHULLAR¹, Varun Dhir², Leishangthem Bidyalaxmi¹, Chandra Bhushan Prasad³, Sankar Jayaprakash¹, Siddharth Jain⁴, Biman Saikia¹, Aman Sharma⁵, Shefali Sharma⁶, Ashok Kumar Yadav¹, Shankar Naidu¹ and Sanjay Jain⁷, ¹PGIMER, Chandigarh, India, ²PGIMER, CHD, INDIA, Chandigarh, India, ³Healthway Hospital, Goa, Zuarinagar, India, ⁴AIIMS, Delhi, India, ⁵PGIMER, Chandigarh, India, Chandigarh, India, ⁶PGIMER< Chandigarh, Chandigarh, India, ⁷Post Graduate Institute of Medical Education and Research, Chandigarh, India
Background/Purpose: Background: GMCSF producing T-cells may be implicated in the pathogenesis of autoimmune diseases like rheumatoid arthritis (RA), multiple sclerosis (MS) and psoriatic arthritis. Few…
Abstract Number: 0206 • ACR Convergence 2023
Risk of Hepatitis B Virus Reactivation in Patients with Rheumatoid Arthritis Receiving JAK Inhibitor or IL-6 Inhibitor: A Systematic Review and Meta-Analysis
Akhil Sood, Janice Lin and Neha Shah, Stanford University, Palo Alto, CA
Background/Purpose: Due to the use of immunosuppressants, patients with rheumatic diseases are at increased risk for Hepatitis B virus (HBV) reactivation. B-cell depleting agents and…
Abstract Number: 0381 • ACR Convergence 2023
Disease Burden, Patient Experiences, and Unmet Needs in Refractory Rheumatoid Arthritis: Insights from 20 Years of Real-World Data
Kristin Wipfler¹, Bobby Kwanghoon Han², Sofia Pedro³, Urbano Sbarigia⁴, Federico Zazzetti⁵, Anna Sheahan⁶, Iris Lin⁷, Patti Katz⁸, Evo Alemao⁹ and Kaleb Michaud¹⁰, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²University of Washington, Seattle, WA, ³Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ⁴Janssen Pharmaceutica, Beerse, Belgium, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶Janssen, Raleigh, NC, ⁷Janssen, Horsham, PA, ⁸University of California San Francisco, San Rafael, CA, ⁹Janssen Pharmaceuticals, New Hope, PA, ¹⁰University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Despite major advances in RA treatment, a substantial number of patients (estimated at 6-21%1) are refractory to multiple advanced therapies. Well-defined refractory RA (reRA)…
Abstract Number: 0397 • ACR Convergence 2023
Obesity Is Associated with Worse Flare Symptoms and Quality of Life in Early Rheumatoid Arthritis: Insights from the RA Flare Questionnaire
Margaret Butler¹, Carlos Aude², Clifton Bingham³ and Vivian Bykerk¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ³Johns Hopkins University, Baltimore, MD
Background/Purpose: Elevated BMI has been previously associated with lower RA remission rates and underascertainment of swollen joint counts.1,2 However, a knowledge gap persists regarding the…
Abstract Number: 0414 • ACR Convergence 2023
Association of a Treat-to-Target Management Approach with Physician and Patient Reported Outcomes Among Real – World Patients with Rheumatoid Arthritis Receiving Advanced Therapy in Europe
Douglas White¹, Aditi Kadakia², Oliver Howell³, Sander Strengholt⁴, Emily Goddard³, Sophie Barlow³ and Tsutomu Takeuchi⁵, ¹Waikato Clinical School, University of Auckland, Hamilton, New Zealand, ²AbbVie, Inc., North Chicago, IL, ³Adelphi Real World, Bollington, United Kingdom, ⁴AbbVie B.V., Mijdrecht, Utrecht, Netherlands, ⁵Keio University School of Medicine and Saitama Medical University, Tokyo, Japan
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease affecting the joints, causing swelling, stiffness, and pain that impact a patient's quality of life. EULAR treatment…
Abstract Number: 0431 • ACR Convergence 2023
Senescence and Cell Exhaustion in CD4+ and CD8+ Lymphocytes in Rheumatoid Arthritis Patients in Remission Without Treatment
Rodolfo Jiménez-Soto¹, Luis llorente², Guadalupe Lima¹, Luisa Alanis Saenz¹, Amairani Gomez Rodriguez¹, Hilda Marin Lopez¹, Erik Cimé-Aké¹ and Juan Jakez-Ocampo¹, ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Departamento de Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: T cells are important among the several risk factors and immunological markers implicated in rheumatoid arthritis (RA). The goal of this study was to…
Abstract Number: 0448 • ACR Convergence 2023
Cardioprotective Impact of JAKi, Tofacitinib, on CV Risk in Rheumatoid Arthritis: JAKi CV Risk Impact Study
Ashit Syngle¹, Inderjeet verma², Nidhi Garg³, Kanchan Chauhan¹, Sapna Patyal¹ and Devaansh Syngle⁴, ¹Healing Touch City Clinic, Chandigarh, India, ²Maharishi Markandeshwar University, Mulana, India, ³Chitkara, Rajpura, India, ⁴Healing Touch Foundation, Chandigarh, India
Background/Purpose: RA patients have at least twice the risk of CVD. In fact, CVD is the leading cause of morbidity and premature mortality in RA.…
Abstract Number: 0487 • ACR Convergence 2023
A Comparative Study of Serositis Between Inpatients with Psoriatic Arthritis and Rheumatoid Arthritis
Ashmia Saif¹, Priyanka Dongare², Meghan Beard³, Yunhan Liao⁴, Xiaoyue Zhang⁴, Qingping Yao⁵ and Asha Patnaik⁶, ¹Stony Brook University Hospital, Syosset, NY, ²Stony Brook University Hospital, Highland, NY, ³Stony Brook Southampton, Moriches, NY, ⁴Biostatistical Consulting Core - Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, ⁵Stony Brook University, Stony Brook, NY, ⁶Stony Brook University Medical Center, East Setauket, NY
Background/Purpose: Autoimmune diseases such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA) can causes erositis including pericarditis and pleuritis. However, the rate of serositis in…
Abstract Number: 0772 • ACR Convergence 2023
MUC5B Promoter Variant and Survival in Rheumatoid Arthritis-Associated Interstitial Lung Disease
Jacob Klein¹, Austin Wheeler¹, Joshua Baker², Yangyuna Yang¹, Punyasha Roul¹, K Wysham³, Gail Kerr⁴, Andreas Reimold⁵, Dana Ascherman⁶, Gary Kunkel⁷, Grant Cannon⁸, Paul Monach⁹, Jill Poole¹, Geoffrey Thiele¹, Ted R Mikuls¹⁰ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³VA Puget Sound/University of Washington, Seattle, WA, ⁴Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁵University of Texas Southwestern Medical Center, Dallas, TX, ⁶University of Pittsburgh, Pittsburgh, PA, ⁷University of Utah, Salt Lake City, UT, ⁸University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁹VA Boston Healthcare System, Boston, MA, ¹⁰Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The gain of function MUC5B rs35705950 promoter variant is the strongest genetic risk factor for the development of RA-ILD (specific to a usual interstitial…
Abstract Number: 0835 • ACR Convergence 2023
Abatacept in Individuals at Risk of Developing Rheumatoid Arthritis: Results from the Arthritis Prevention in the Pre-clinical Phase of RA with Abatacept (APIPPRA) Trial
Andrew Cope¹, Marianna Jasenecova², Joana Vasconcelos³, Andrew Filer⁴, Karim Raza⁵, Sumera Qureshi², Maria Antonietta D'Agostino⁶, Iain McInnes⁷, John Isaacs⁸, Arthur Pratt⁹, Benjamin A Fisher⁴, Christopher Buckley¹⁰, Paul Emery¹¹, Pauline Ho¹², Maya Buch¹³, Coziana Ciurtin¹⁴, René Toes¹⁵, Thomas Huizinga¹⁵, Dirkjan van Schaardenburg¹⁶, Caroline Caroline¹⁷ and Toby Prevost³, ¹King's College London, London, United Kingdom, ²Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ³Nightingale-Saunders Clinical Trials & Epidemiology Unit, King's College London, London, United Kingdom, ⁴University of Birmingham, Birmingham, United Kingdom, ⁵Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁶Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy, ⁷University of Glasgow, Glasgow, United Kingdom, ⁸Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom, ⁹Translational & Clinical Research Institute, University of Newcastle, Newcastle, United Kingdom, ¹⁰University of Oxford, Oxford, United Kingdom, ¹¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ¹²Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ¹³University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, ¹⁴Centre for Rheumatology Research, University College London, London, United Kingdom, ¹⁵Leiden University Medical Center, Leiden, Netherlands, ¹⁶Reade, Amsterdam, Netherlands, ¹⁷King's Clinical Trials Unit, King's College London, London, United Kingdom
Background/Purpose: The definition of higher risk states for rheumatoid arthritis (RA) has been refined in more recent years through inclusion of serum autoantibodies and symptom…
Abstract Number: 0982 • ACR Convergence 2023
Systemic Autoimmune Rheumatic Diseases (SARD) in the Agricultural Health Study Cohort: Rates of Rheumatoid Arthritis (RA) and Other SARD Among Medicare-linked Participants
Christine Parks¹, Karen Costenbader², Laura Beane Freeman³, Jonathan Hofmann³ and Dale Sandler⁴, ¹Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, ⁴Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Durham, NC
Background/Purpose: Some systemic autoimmune rheumatic diseases (SARD), such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), have been associated with farming, specific pesticides, and…
Abstract Number: 1034 • ACR Convergence 2023
The Relationship Between the Extent of Ground Glass to Fibrosis Ratio and Treatment Response to Immunomodulatory Therapy in Three Separate Autoimmune Interstitial Lung Disease Cohorts
Scott Matson¹, Stephen Humphries², joyce Lee³, Michael Roth⁴, Donald Tashkin⁴, Grace Kim⁴, Jonathan Goldin⁴, Mei Leng⁴ and Elizabeth Volkmann⁴, ¹University of Kansas School of Medicine, Kansas City, MO, ²National Jewish Health, Denver, CO, ³University of Colorado Anschutz Campus, Denver, CO, ⁴University of California Los Angeles, Los Angeles, CA
Background/Purpose: For patients with autoimmune interstitial lung disease (ILD), the clinician's interpretation of the extent of ground glass relative to fibrosis on imaging often influences…
Abstract Number: 1265 • ACR Convergence 2023
Changes in the Endocannabinoid Tone in Rheumatoid Arthritis and Osteoarthritis – Discovery of a Novel Target for the Treatment of Pain and Inflammation?
Jost Klawitter¹, Andrew Clauw¹, Jennifer Seifert¹, Jelena Klawitter¹, Bridget Tompson¹, Cristina Sempio¹, Uwe Christians¹ and Larry Moreland², ¹University of Colorado Anschutz Medical Campus, Aurora, CO, ²University of Colorado, Denver, CO

Background/Purpose: Inflammation is a complicated physiological process that results in a variety of disorders. Several inflammatory mediators are produced during this process, which is responsible…
Abstract Number: 1281 • ACR Convergence 2023
Risk of Cancer in Patients with Rheumatoid Arthritis Under Tocilizumab: Data from the French National Registry REGATE
JACQUES MOREL¹, Amélie Wetzman², Daniel Wendling³, Martin Soubrier⁴, Olivier Roth⁵, Jacques-Eric Gottenberg⁶, Philippe Goupille⁷, Xavier Mariette⁸ and Cedric Lukas⁹, ¹Protocole thérapeutique immuno-rhumatologie, Montpellier, France, ²CHU and University of Montpellier, Narbonne, France, ³Besançon University Hospital, Besançon, France, ⁴Gabriel-Montpied Hospital, Clermont-ferrand, France, ⁵Saint Joseph Hospital, Marseille, France, ⁶Rheumatology Department, Strasbourg University Hospital, Strasbourg, France, ⁷CHU and University of Tours, Tours, France, ⁸Université Paris-Saclay, Le Kremlin-Bicêtre, France, ⁹CHU Montpellier, Montpellier, France
Background/Purpose: Our study aimed to estimate the incidence and risk factors of cancer among rheumatoid arthritis (RA) patients treated with tocilizumab (TCZ) and followed for…
Abstract Number: 1297 • ACR Convergence 2023
COVID-19 Vaccination-related Delayed Adverse Events Among Patients with Rheumatoid Arthritis: Results from the COVAD Study
Mrinalini Dey¹, Bohdana Doskaliuk², Ioannis Parodis³, Julius Lindblom³, Chris Wincup⁴, Mrudula Joshi⁵, Dey Dzifa⁶, Esha Kadam⁷, Parikshit Sen⁸, Samuel Shinjo⁹, Arvind Nune¹⁰, Nelly Ziade¹¹, Yi-Ming Chen¹², Lisa Traboco¹³, CARLOS ENRIQUE TORO GUTIERREZ¹⁴, COVAD Study Group¹⁵, Rohit Aggarwal¹⁶, Vikas Agarwal¹⁷, Latika Gupta¹⁸ and Elena Nikiphorou¹⁹, ¹Queen Elizabeth Hospital, London, United Kingdom; University of Liverpool, Liverpool, United Kingdom, ²SHEI "Ivano-Frankivsk national medical university", Ivano-Frankivsk, Ukraine, ³Karolinska Institutet, Stockholm, Sweden, ⁴King's College Hospital, London, United Kingdom, ⁵Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India, ⁶Department of Medicine and Therapeutics, University of Ghana School of Medicine and Dentistry, College of Health Sciences, Korle-Bu, Accra, Ghana, ⁷Seth Gordhandhas Sunderdas Medical College and King Edwards Memorial Hospital, Mumbai, India, ⁸Maulana Azad Medical College, 2-Bahadurshah Zafar Marg, New Delhi, Delhi-110002, India., Dalhi, India, ⁹Faculdade de Medicina FMUSP, Universidade de Sao Paulo, São Paulo, Brazil, ¹⁰Southport & Ormskirk NHS Foundation Trust, Liverpool, United Kingdom, ¹¹Saint-Joseph University, Beirut, Lebanon, ¹²Taichung Veterans General Hospital, Taichung, Taiwan, ¹³University of the Philippines - Manila, St Luke's Medical Center - Bonifacio Global City, Paranaque, Manila, Philippines, ¹⁴Centro de Estudios de Reumatología y Dermatología SAS, Cali, Colombia, ¹⁵-, -, ¹⁶University of Pittsburgh, Pittsburgh, PA, ¹⁷Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ¹⁸Royal Wolverhampton Trust, Wolverhampton/University of Manchester, United Kingdom, ¹⁹King's College London, London, United Kingdom
Background/Purpose: COVID-19 vaccines have been proven to be safe in the healthy population. Data on longer-term AEs in people with autoimmune diseases (AIDs), including rheumatoid…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].